COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Daratumumab, Pomalidomide And Dexamethasone (Dpd) In Relapsed/ Refractory Light Chain Amyloidosis Patients Previously Exposed To Daratumumab

Protocol No
WEILLCORNELL-AMY2006-DPD
Principal Investigator
Anita D'Souza
Phase
II
Summary
The purpose of this study is to assess the tolerability and safety of an investigational combination of drugs in relapsed/refractory AL amyloidosis.
Description
DPd in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL